SERA — Sera Prognostics Inc
NASDAQ · Healthcare · Medical Devices
$2.10
+$0.02 (+1.20%)
Sera Prognostics Inc (SERA) is a medical devices company listed on NASDAQ. It is led by Zhenya Lindgardt M.B.A., based in 2749 East Parleys Way, Salt Lake City, UT, United States, 84109, with about 71 employees. Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Latest reported SERA revenue for 2025-09-30 was $16.0K. Net income was -$7.8M. Revenue was down 5.9% from 2025-06-30 to 2025-09-30. SERA currently screens at market cap $89.1M.
Use this SERA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the SERA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the SERA SEC filings page. Lician reads the product cache first so this HTML stays unique to Sera Prognostics Inc even when a live quote feed is slow.
About Sera Prognostics Inc
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
SERA Key Statistics
Market Cap
$89.09M
Volume
6,421
Previous Close
$2.18
Day Range
$2.13 – $2.18
EPS
-$0.99
Revenue
$77.00K
Net Income
-$32.90M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-74.8%
Profit Margin
-42724.7%
Employees
71
SERA Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $77.00K | $306.00K | $268.00K | $82.00K |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$32.90M | -$36.24M | -$44.19M | -$35.01M |
| EPS (Diluted) | -$0.99 | -$1.16 | -$1.43 | -$2.33 |
Total Assets
$72.58M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$4.04M
Operating Cash Flow
-$14.19M
Free Cash Flow
$0.00
Sera Prognostics Inc Company Information
- President, CEO & Director
- Zhenya Lindgardt M.B.A.
- Headquarters
- 2749 East Parleys Way, Salt Lake City, UT, United States, 84109
- Website
- www.sera.com
- Phone
- 801 990 0520
- IPO / Founded
- 2021-07-15
- Sector
- Healthcare
- Industry
- Medical Devices